Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37702529)
Watch
English
Targeted therapy for renal cell carcinoma: The next lap.
scientific article published on 20 February 2014
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
title
Targeted therapy for renal cell carcinoma: The next lap
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
main subject
renal cell carcinoma
1 reference
based on heuristic
inferred from title
author
Ravindran Kanesvaran
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
author name string
Min-Han Tan
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
language of work or name
English
0 references
publication date
20 February 2014
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
published in
Journal of Carcinogenesis
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
volume
13
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
page(s)
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
cites work
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Integrated molecular analysis of clear-cell renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Comprehensive molecular characterization of clear cell renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Cancer genome landscapes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Trastuzumab emtansine for HER2-positive advanced breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
BAP1 loss defines a new class of renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Targeting mTOR in cancer: renal cell is just a beginning
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Targeting mTOR in renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Defining the role of mTOR in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Sorafenib in advanced clear-cell renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
CD133+ renal progenitor cells contribute to tumor angiogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
TOR signaling in growth and metabolism
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Negative regulation of T-cell function by PD-1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Gene expression profiling of renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Prospective identification of tumorigenic breast cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
CD105 (endoglin) expression on hematopoietic stem/progenitor cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Identification of the von Hippel-Lindau disease tumor suppressor gene
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 August 2017
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
6 September 2017
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
6 September 2017
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
6 September 2017
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
6 September 2017
Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
28 September 2017
Resident stem cells and renal carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 June 2018
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
23 June 2018
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
1 September 2018
The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
1 September 2018
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
1 September 2018
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
1 September 2018
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
1 September 2018
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
1 September 2018
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3986548
retrieved
3 December 2018
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Microvesicles Released from Human Renal Cancer Stem Cells Stimulate Angiogenesis and Formation of Lung Premetastatic Niche
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Differentiation Therapy: Targeting Human Renal Cancer Stem Cells with Interleukin 15
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identification of a tumor-initiating stem cell population in human renal carcinomas
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24737951
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.4103/1477-3163.127638
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
PMC publication ID
3986548
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
PubMed publication ID
24737951
1 reference
stated in
Europe PubMed Central
PMC publication ID
3986548
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737951%20AND%20SRC:MED&resulttype=core&format=json
retrieved
14 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
